摘要
新药研发是一个迷人的学科包括医学的各个方面,例如药理学,生物技术和化学。在人类患者中新的临床申请的有效性和安全性使得新药研发受到限制。药品监管当局为安全的新化学成分提供了不同的指导方针,必须在临床试验中严格遵守。尽管如此,各种药物在临床试验中失败或退出市场,因为与人类相关的毒性、肝毒性、神经毒性和致畸性问题。安全预测的失败是指物种特异性问题,缺乏机械的毒性数据和临床试验的不足。这些药物不仅影响人类健康,而且造成资源和时间的损失。该物种特异性问题主要利用人体细胞解决但他们的可用性是非常有限的。人类胚胎干细胞(为)和诱导多能干细胞(hiPSCs)提供无限数量的人体细胞的产生来源。毒性测试机械模型的出现为设计新的人类相关测试策略铺平了道路设计新的人类相关的测试策略,这种机械模型基于胚胎干细胞和人iPS细胞的蛋白质组学研究与转录组学,毒代动力学读数同步。在体外药代动力学研究中及在平行的导线选择和优化的时间内,这些模型的引入通过安全先导分子的选择将大大降低复合损耗率。我们专注于即将到来的胚胎干细胞和人iPS细胞的毒性试验模型和未来的角色来解决目前药物发现和开发的安全漏洞。
关键词: 多能干细胞、致畸性、毒性、肝毒性、神经毒性、新药发现、选择测试策略。
Current Medicinal Chemistry
Title:Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Volume: 23 Issue: 30
Author(s): Vaibhav Shinde, Poornima Sureshkumar, Isaia Sotiriadou, Jurgen Hescheler, Agapios Sachinidis
Affiliation:
关键词: 多能干细胞、致畸性、毒性、肝毒性、神经毒性、新药发现、选择测试策略。
摘要: New drug discovery (NDD) is a fascinating discipline encompassing different facets of medicine, pharmacology, biotechnology and chemistry. NDD is very often restricted by efficacy or safety problems of the new clinical candidate in human patients. Drug regulatory authorities have provided various guidelines for advancement of safe new chemical entities (NCEs) in clinical trials which must be strictly followed. In spite of this, various drugs have failed in clinical trials or withdrawn from market because of human safety issues related to cardiotoxicity, hepatotoxicity, neurotoxicity and teratogenicity. The failure of safety prediction was pointed to species specificity issues, lack of mechanistic toxicity data and inadequate clinical trials. These drugs not only affect human health but also cause loss of resources and time. The species specificity issues are partially addressed by use of primary human cells but their availability is very limited. Human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) offer sources for generation of an unlimited number of human somatic cells. The emergence of mechanistic models for toxicity testing with transcriptomics, proteomics along with toxicokinetics readouts based on hESCs and hiPSCs is paving the way to design new human relevant testing strategies. Introduction of these models at the timeframe of lead selection and optimization in parallel with in vitro pharmacokinetic studies will significantly reduce compound attrition rate by selection of safer lead molecules. We focused on upcoming hESCs and hiPSCs based toxicity testing models and their future role to address safety gaps of present drug discovery and development.
Export Options
About this article
Cite this article as:
Vaibhav Shinde, Poornima Sureshkumar, Isaia Sotiriadou, Jurgen Hescheler, Agapios Sachinidis , Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery, Current Medicinal Chemistry 2016; 23 (30) . https://dx.doi.org/10.2174/0929867323666160627113436
DOI https://dx.doi.org/10.2174/0929867323666160627113436 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases
Current Pharmaceutical Design Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets Aptamers: Potential Applications to Pancreatic Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology New Insights in Congenital Diaphragmatic Hernia
Current Respiratory Medicine Reviews Synthesis and Pharmacological Evaluation of Novel 4-Alkyl-5-thien-2’-yl Pyrazole Carboxamides
Central Nervous System Agents in Medicinal Chemistry Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets The Clinical Relevance of Advanced Glycation Endproducts (AGE) and Recent Developments in Pharmaceutics to Reduce AGE Accumulation
Current Medicinal Chemistry Retropharyngeal Abscess: Diagnosis and Treatment Update
Infectious Disorders - Drug Targets Citrobacter braakii Bacteremia: Case Report and Review of the Literature
Infectious Disorders - Drug Targets Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Retromer's Role in Endosomal Trafficking and Impaired Function in Neurodegenerative Diseases
Current Protein & Peptide Science Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention
Current Medicinal Chemistry Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Unique Insights into the Actions of CNS Agents: Lessons from Studies of Chlorpyrifos and Other Common Pesticides
Central Nervous System Agents in Medicinal Chemistry Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design